Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Now watching

Next video starts in : 7 Play

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People
Replay video
Up next

United Technologies, Data: What to Watch on Wall Street April 21

Unlock your personal NFL Now stream by signing in to NFL.com

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

by TheStreet 1:02 mins

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

by TheStreet 1:02 mins

New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York.

TheStreet

Market Movers

  1. 14:01

    Wall Street's China Boost; Hasbro gains from boys' toys; Target's Lilly Pulitzer sales craze

  2. 1:48

    Morgan Stanley's 'strongest quarter in years'; Hasbro's boy power; Raytheon gets into cybersecurity

  3. 2:35

    Target's Lilly Pulitzer line overwhelmed by demand

  4. 2:17

    Comcast and Time Warner Cable to meet with Justice Department: Report

  5. 1:57

    Raytheon planning new cyber security venture

  6. 1:46

    Jon Corzine seeks to launch hedge fund: Report